35 results about "Thyroid papillary carcinoma" patented technology

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

The invention discloses application of an immune colloidal gold test strip for detecting thyroglobulin in preparation of a tool for rapidly detecting a thyroglobulin value of a suspicious lymph node on site in an operation and relates to the technical field of immunoassay. In the application, the immune colloidal gold test strip comprises a sample pad, a gold label pad, a nitrocellulose film and a water absorption pad which are partially spliced on a PVC (polyvinyl chloride) bottom plate in sequence, the gold label pad is coated with a colloidal gold labeled anti-thyroglobulin antibody, and a detection line and a quality control line which are separated are arranged on the nitrocellulose film. The detection line is coated with another anti-thyroglobulin antibody, and the quality control line is coated with goat anti-mouse IgG. The invention further provides application of the immune colloidal gold test strip in preparation of a tool for auxiliary diagnosis of lymph node metastasis of papillary thyroid carcinoma and application of the immune colloidal gold test strip in preparation of a tool for detecting thyroglobulin value in lymph node fine needle puncture suction eluent.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilia syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

The invention relates to a gene related to papillary thyroid cancer and its application. According to the base sequence of the gene, real-time quantitative PCR primers are designed and synthesized, and the long-chain non-coding transcribed by the gene is detected in clinical case samples of papillary thyroid cancer. The expression level of RNA was found to be significantly down-regulated in papillary thyroid tumor tissue, and gene silencing of the long non-coding RNA could significantly promote the growth of thyroid cancer cells. The invention is expected to prepare preparations for auxiliary diagnosis, gene therapy, curative effect prediction or prognosis judgment of papillary thyroid cancer.

The present invention proposes miRNA biomarkers and detection kits for the diagnosis of cervical lymph node metastasis of papillary thyroid carcinoma, the miRNAs are hsa-miR-146b, hsa-miR-25-3p, hsa-miR-296- 5p, hsa-miR-222-3p, hsa-miR-21 and hsa-miR-95 combination; detection kit comprising primers capable of amplifying said miRNA biomarkers and probes capable of detecting said miRNA biomarkers . The six miRNAs of the present invention are stably expressed in serum, and they are combined as biomarkers for the diagnosis of lateral cervical lymph node metastasis of thyroid cancer, and the sensitivity and specificity of the diagnosis are significantly higher than those of a single miRNA. The present invention uses serum miRNA to diagnose cervical lymph node metastasis in patients with papillary thyroid carcinoma. Compared with traditional pathological biopsy, the invention has less trauma and is suitable for preoperative diagnosis of patients who are difficult to perform lymph node puncture due to anatomical location and other reasons. , and can be repeated during patient follow-up.

The present invention provides a liquid biopsy kit for diagnosing lymph node metastasis of papillary thyroid carcinoma, comprising: a reagent for detecting hsa-circ-UMAD1; and a reagent for detecting galectin-3. The invention constructs a combined detection technology of plasma hsa‑circ‑UMAD1 combined with galectin 3, which provides important evidence for evaluating lymph node metastasis in patients with papillary thyroid carcinoma.

The invention discloses a fluorescent immunochromatography test paper for rapidly detecting human thyroglobulin (Tg) to rapidly identify cervical lymph node metastasis of papillary thyroid carcinoma. The test paper detects human Tg by double antibody sandwich method and fluorescent immunochromatography technology. Antibodies are prepared using specific epitope peptides. The invention can quickly and accurately detect the human Tg in the object to be tested, and has the advantages of simple and rapid operation, wide detection range, high specificity and good sensitivity.